This section of the website is only for UK patients that have been prescribed KEYTRUDA. If you are a UK healthcare professional, please click here. If you are a member of the UK public, please click here.

Welcome to the 
KEYTRUDA
® (pembrolizumab)
patient website

Here you can find support tools and information to help you understand your diagnosis and treatment:

This website contains information about melanoma, non-small cell lung cancer (NSCLC), classical Hodgkin Lymphoma (cHL) and bladder cancer, your treatment for advanced melanoma, advanced NSCLC, relapsed or refractory cHL and advanced bladder cancer, the potential side effects and some support tools that should be available from your Healthcare Professional (HCP).

The information provided on this website is general educational information and does not take the place of your healthcare professional's medical advice. Always follow your HCP’s instructions and talk with him/her about any questions or problems you have regarding your health and treatment.

Pembrolizumab belongs to a type of cancer treatment called immunotherapy. This type of drug works with your body’s immune system, by increasing its natural ability to identify and attack cancer cells.

If you notice any symptoms while receiving your treatment, you should talk to your Healthcare Professional right away.  Be aware that side effects may occur after receiving the final dose of your treatment and can affect more than one body area. Your healthcare team will provide a copy of the Patient Safety Information Brochure and Patient Alert Card which provide information about your treatment. Please ensure you read the brochure and carry the alert card with you at all times. By reporting side affects you can help provide more information on the safety of this medicine.

Contact Us

Your Details

Your Question

Send Form